Compare MVST & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MVST | FENC |
|---|---|---|
| Founded | 2006 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 266.7M | 384.3M |
| IPO Year | 2019 | 2010 |
| Metric | MVST | FENC |
|---|---|---|
| Price | $0.64 | $10.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $6.00 | ★ $14.50 |
| AVG Volume (30 Days) | ★ 6.4M | 239.6K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 85.25 | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | ★ $427,516,000.00 | $44,642,000.00 |
| Revenue This Year | $24.55 | $65.12 |
| Revenue Next Year | $17.08 | $41.08 |
| P/E Ratio | ★ N/A | $177.67 |
| Revenue Growth | ★ 12.56 | N/A |
| 52 Week Low | $0.59 | $5.65 |
| 52 Week High | $7.12 | $13.25 |
| Indicator | MVST | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 28.83 | 40.04 |
| Support Level | N/A | $9.74 |
| Resistance Level | $1.02 | $11.28 |
| Average True Range (ATR) | 0.04 | 0.58 |
| MACD | -0.01 | -0.24 |
| Stochastic Oscillator | 10.58 | 19.77 |
Microvast Holdings Inc develops lithium-ion battery technologies focused on high-performance solutions for commercial and industrial electrification. The Company designs, develops, and manufactures battery components and systems for electric commercial vehicles and energy storage systems (ESS), with applications across buses, trucks, port equipment, and mining machinery. It emphasizes innovation in battery design without relying on legacy technologies and supports platforms such as the IVECO eDaily and various bus models. The Company also provides services, repairs, and warranty and extended warranty support. It operates as a single reportable segment, covering design, development, manufacturing, sales, and leasing of battery systems, and generates the majority of its revenue from Europe.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.